Compare iShares Broad USD Investment Grade Corporate Bond (USIG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Broad USD Investment Grade Corporate Bond vs State Street SPDR S&P Biotech ETF — how do they compare? iShares Broad USD Investment Grade Corporate Bond trades at $48.77 (market cap $17.53B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: iShares Broad USD Investment Grade Corporate Bond is the larger of the two by market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Broad USD Investment Grade Corporate Bond for 44 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| USIG | XBI | |
|---|---|---|
Market Cap | $17.53B | $10.11B |
Volume | 4,695,583 | 12,903,266 |
Sector | Fixed Income | Broad Market / Factor |
52-Week High | $52.69 | $169.55 |
52-Week Low | $48.54 | $104.99 |
Typical Hold Time | 44 Days | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
USIG trades at $48.765 with minimal daily movement (+0.17%). Technical indicators show a bearish bias with moving averages signaling caution, though oscillators remain neutral. The stock faces resistance at $49 levels while finding support at $48. Recent institutional activity includes Blue Edge Capital's new $21.9 million position and Bank of New York Mellon's increased stake, indicating institutional confidence.
The bearish technical setup contrasts with institutional accumulation, creating a divergence worth monitoring. Key risks include market volatility and competitive pressures in the investment grade corporate bond ETF space. The absence of current fundamental metrics requires careful due diligence on underlying bond portfolio quality and interest rate sensitivity.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
